Company: IONQ
Filing Date: 2025-10-10
Form Type: 424B5
Source: 0001193125-25-236452
Chunk: 8

Company: IonQ, Inc.
Filing Date: 2025-10-10
Form: 424B5
Chunk 8
---
, resulting in a loss of all or part of your investment. Please also read carefully the section below titled “Forward-Looking Statements.”

Additional risks related to the offering

We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will
have broad discretion in the application of the net proceeds. We currently intend to use the net proceeds from this offering for working capital and other general corporate purposes, including to enter into strategic acquisitions and partnerships.
Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our
business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.

Any purchaser in this offering will experience immediate and substantial dilution in the net tangible book value of shares purchased in this offering.

Since the offering price per share in this offering is substantially higher than the net tangible book value per share of our
common stock outstanding prior to this offering, any purchaser in this offering will suffer substantial dilution in the net tangible book value of shares purchased in this offering. Based on the public offering price of $93.00 per share and our
estimated aggregate net proceeds of $1,978.5 million from this offering, after deducting underwriting discounts and estimated offering expenses payable by us (but excluding shares issued and any proceeds received upon exercise of the Warrants),
the purchasers will experience immediate dilution of $83.92 per share, representing the difference between our as adjusted net tangible book value per share as of June 30, 2025, after giving effect to this offering and the public offering price
per share of common stock. The exercise of outstanding stock options, the vesting of outstanding restricted stock units and the exercise of warrants would result in further dilution of such investment. See the section titled “Dilution”
below for a more detailed illustration of the dilution you would incur if you participate in this offering.

Future sales or issuances of our common stock in the public markets, including sales by our directors and officers, or the perception of such sales, could depress the trading price of our common stock.

The sale of a substantial number of shares of our common stock or other